Articles by Amy Ritter, PhD - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Amy Ritter, PhD

Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 Billion

Jul 23, 2012

Sandoz announced it has completed the acquisition of Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.5 billion.

CHMP Recommends Approval for First Gene Therapy

Jul 20, 2012

EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Glybera (alipogene tiparvovec, marking the first recommendation in Europe for a gene therapy medicine.

Par Pharmaceuticals to be Acquired by TPG for $1.9 Billion

Jul 18, 2012

Par Pharmaceuticals, a maker of generic drugs, has entered into an agreement to be acquired by the private investment firm, TPG.

FDA Introduces New Safety Measures for Opioid Medications

Jul 11, 2012

FDA approved a risk evaluation and mitigation strategy for extended-release and long-acting opioid medications.

GSK Agrees to $3-Billion Settlement with Justice Department

Jul 3, 2012

GlaxoSmithKline has agreed to plead guilty and pay $3 billion to resolve criminal and civil liability resulting from unlawful promotion of certain drugs, failure to report safety data, and alleged false price reporting practices.

Optimizing Expression Systems

Industry experts from Fujifilm Diosynth and Boehringer Ingelheim discuss methods for optimizing protein expression in bacterial and mammalian cell lines.
Jul 1, 2012

Industry experts discuss methods for optimizing protein expression in bacterial and mammalian cell lines.

US Supreme Court Upholds Individual Mandate for Health Insurance

Jun 28, 2012

In a 5-4 ruling, the US Supreme Court upheld the provision of the Affordable Care Act requiring all adults to purchase health insurance or pay a penalty—the so-called individual mandate.

Roche to Close US R&D Site

Jun 27, 2012

Roche announced that it will be closing its R&D site in Nutley, NJ, eliminating approximately 1000 positions.

Eli Lilly Expands Manufacturing Base in China

Jun 13, 2012

Eli Lilly announced an increase in its manufacturing network in China through an expanded collaboration with Novast Laboratories, a generic and specialty pharmaceutical company based in Nantong, China.

ADVERTISEMENT

ADVERTISEMENT

Click here